{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:04:50Z","timestamp":1789524290181,"version":"build-2803163510"},"reference-count":67,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Deutsche Forschungsgemeinschaft"},{"name":"Heidelberg University"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Marfan syndrome (MFS) is one of the most common inherited disorders of connective tissue caused by mutations of the fibrillin-1 gene (FBN1). Vascular abnormalities, such as the enlargement of the aorta with the risk of life-threatening rupture are frequently observed. However, current treatment is limited and therapeutic options focus solely on symptomatic therapy. Gene therapy focuses on genetically modifying cells to produce a therapeutic effect and may be a promising treatment option for MFS. Here, we first provide an overview of the historical background and characterization of MFS. Subsequently, we summarise current gene therapy options and possible translational concepts for this inherited disorder that affects connective tissue.<\/jats:p>","DOI":"10.3390\/jcm11143934","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T09:41:10Z","timestamp":1657100470000},"page":"3934","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Translational Medicine: Towards Gene Therapy of Marfan Syndrome"],"prefix":"10.3390","volume":"11","author":[{"given":"Klaus","family":"Kallenbach","sequence":"first","affiliation":[{"name":"Institute for Cardiac Surgery and Interventional Cardiology (INCCI), Department of Cardiac Surgery, 1210 Luxembourg, Luxembourg"},{"name":"VASCERN HTAD European Reference Center, 1210 Luxembourg, Luxembourg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Remes","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University of Kiel and University Hospital Schleswig-Holstein, 24105 Kiel, Germany"},{"name":"German Centre for Cardiovascular Research, Partner Site Hamburg\/Kiel\/L\u00fcbeck, 20251 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8223-2638","authenticated-orcid":false,"given":"Oliver J.","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University of Kiel and University Hospital Schleswig-Holstein, 24105 Kiel, Germany"},{"name":"German Centre for Cardiovascular Research, Partner Site Hamburg\/Kiel\/L\u00fcbeck, 20251 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawa","family":"Arif","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, University Hospital Heidelberg, 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Zaradzki","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, University Hospital Heidelberg, 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2723-5953","authenticated-orcid":false,"given":"Andreas H.","family":"Wagner","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Physiology, Heidelberg University, Im Neuenheimer Feld 326, 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ajmg.1320290316","article-title":"International Nosology of Heritable Disorders of Connective Tissue, Berlin, 1986","volume":"29","author":"Beighton","year":"1988","journal-title":"Am. J. Med. Genet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/352337a0","article-title":"Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene","volume":"352","author":"Dietz","year":"1991","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/(SICI)1096-8628(19960424)62:4<417::AID-AJMG15>3.0.CO;2-R","article-title":"Revised diagnostic criteria for the Marfan syndrome","volume":"62","author":"Devereux","year":"1996","journal-title":"Am. J. Med. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/jmg.2009.072785","article-title":"The revised Ghent nosology for the Marfan syndrome","volume":"47","author":"Loeys","year":"2010","journal-title":"J. Med. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1038\/s41436-018-0399-4","article-title":"Marfan syndrome: Improved clinical history results in expanded natural history","volume":"21","author":"Pyeritz","year":"2019","journal-title":"Genet. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"12021","DOI":"10.1038\/s41598-019-48572-9","article-title":"The reimplantation valve-sparing aortic root replacement technique for patients with Marfan syndrome: A single-center experience","volume":"9","author":"Kremer","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/14017431.2020.1869298","article-title":"Outcome of valve sparing root replacement for diverse indications","volume":"55","author":"Huuskonen","year":"2021","journal-title":"Scand. Cardiovasc. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1136\/heartjnl-2021-319300","article-title":"Personalised external aortic root support for elective treatment of aortic root dilation in 200 patients","volume":"107","author":"Rega","year":"2021","journal-title":"Heart"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/S0140-6736(19)32518-8","article-title":"Irbesartan in Marfan syndrome (AIMS): A double-blind, placebo-controlled randomised trial","volume":"394","author":"Mullen","year":"2019","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e008543","DOI":"10.1161\/JAHA.118.008543","article-title":"Statins Reduce Thoracic Aortic Aneurysm Growth in Marfan Syndrome Mice via Inhibition of the Ras-Induced ERK (Extracellular Signal-Regulated Kinase) Signaling Pathway","volume":"7","author":"Sato","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bcp.2019.03.034","article-title":"Marfan syndrome: A therapeutic challenge for long-term care","volume":"164","author":"Wagner","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2147\/JEP.S265271","article-title":"An Overview of Investigational and Experimental Drug Treatment Strategies for Marfan Syndrome","volume":"13","author":"Deleeuw","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.omtn.2017.08.014","article-title":"AP-1 Oligodeoxynucleotides Reduce Aortic Elastolysis in a Murine Model of Marfan Syndrome","volume":"9","author":"Arif","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/cvr\/cvab012","article-title":"AAV-mediated AP-1 decoy oligonucleotide expression inhibits aortic elastolysis in a mouse model of Marfan syndrome","volume":"117","author":"Remes","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e023601","DOI":"10.1161\/JAHA.121.023601","article-title":"Vascular Smooth Muscle Cells in Aortic Aneurysm: From Genetics to Mechanisms","volume":"10","author":"Lu","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"571076","DOI":"10.3389\/fcvm.2021.571076","article-title":"Unresolved Issues in RNA Therapeutics in Vascular Diseases With a Focus on Aneurysm Disease","volume":"8","author":"Schellinger","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nature15818","article-title":"Gene therapy returns to centre stage","volume":"526","author":"Naldini","year":"2015","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Seppelt, P.C., Schwill, S., Weymann, A., Arif, R., Weber, A., Zaradzki, M., Richter, K., Ensminger, S., Robinson, P.N., and Wagner, A.H. (2016). Loss of Endothelial Barrier in Marfan Mice (mgR\/mgR) Results in Severe Inflammation after Adenoviral Gene Therapy. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0148012"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/cvr\/cvr197","article-title":"Plasmid-mediated gene therapy for cardiovascular disease","volume":"91","author":"Williams","year":"2011","journal-title":"Cardiovasc. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1161\/CIRCRESAHA.114.302331","article-title":"Adeno-associated virus vectors as therapeutic and investigational tools in the cardiovascular system","volume":"114","author":"Zacchigna","year":"2014","journal-title":"Circ. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.omtm.2021.02.017","article-title":"Alginate hydrogel polymers enable efficient delivery of a vascular-targeted AAV vector into aortic tissue","volume":"21","author":"Remes","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/gt.2017.82","article-title":"Stent-based delivery of adeno-associated viral vectors with sustained vascular transduction and iNOS-mediated inhibition of in-stent restenosis","volume":"24","author":"Fishbein","year":"2017","journal-title":"Gene Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer","volume":"28","author":"Verdera","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"114265","DOI":"10.1016\/j.bcp.2020.114265","article-title":"Gene transfer to the vascular system: Novel translational perspectives for vascular diseases","volume":"182","author":"Remes","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1161\/HYPERTENSIONAHA.120.14478","article-title":"Progress of Gene Therapy in Cardiovascular Disease","volume":"76","author":"Shimamura","year":"2020","journal-title":"Hypertension"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"24413","DOI":"10.1038\/srep24413","article-title":"Generation of heterozygous fibrillin-1 mutant cloned pigs from genome-edited foetal fibroblasts","volume":"6","author":"Umeyama","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/ajmg.1320370137","article-title":"An animal model of the Marfan syndrome","volume":"37","author":"Besser","year":"1990","journal-title":"Am. J. Med. Genet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/humu.20152","article-title":"Bovine model of Marfan syndrome results from an amino acid change (c.3598G > A, p.E1200K) in a calcium-binding epidermal growth factor-like domain of fibrillin-1","volume":"25","author":"Singleton","year":"2005","journal-title":"Hum. Mutat."},{"key":"ref_29","first-page":"206","article-title":"Overexpression of TIMP-2 mediated by recombinant adenovirus in rat abdominal aorta inhibits extracellular matrix degradation","volume":"2","author":"Zhao","year":"2008","journal-title":"Biosci. Trends"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.jvs.2008.04.016","article-title":"Elastic fibers reconstructed using adenovirus-mediated expression of tropoelastin and tested in the elastase model of abdominal aortic aneurysm in rats","volume":"48","author":"Xiong","year":"2008","journal-title":"J. Vasc. Surg."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1089\/hum.2016.144","article-title":"Angiotensin-Converting Enzyme 2 Inhibits Angiotensin II-Induced Abdominal Aortic Aneurysms in Mice","volume":"29","author":"Hao","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e004968","DOI":"10.1161\/JAHA.116.004968","article-title":"Aortopathy in a Mouse Model of Marfan Syndrome Is Not Mediated by Altered Transforming Growth Factor \u03b2 Signaling","volume":"6","author":"Wei","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Kielbasa, S.M., Gonze, D., and Herzel, H. (2005). Measuring similarities between transcription factor binding sites. BMC Bioinform., 6.","DOI":"10.1186\/1471-2105-6-237"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2174\/1568026615666150413154713","article-title":"Targeting Transcription Factor Binding to DNA by Competing with DNA Binders as an Approach for Controlling Gene Expression","volume":"15","author":"Bouhlel","year":"2015","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","article-title":"Therapeutic Antisense Oligonucleotides Are Coming of Age","volume":"70","author":"Bennett","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"8771","DOI":"10.7150\/thno.62642","article-title":"Effective tools for RNA-derived therapeutics: siRNA interference or miRNA mimicry","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.tibs.2007.02.006","article-title":"A developmental view of microRNA function","volume":"32","author":"Zhao","year":"2007","journal-title":"Trends Biochem. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"174178","DOI":"10.1016\/j.ejphar.2021.174178","article-title":"siRNA: Mechanism of action, challenges, and therapeutic approaches","volume":"905","author":"Alshaer","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bcp.2017.06.122","article-title":"Transcription factor decoy technology: A therapeutic update","volume":"144","author":"Hecker","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Hecker, M., Wagner, S., Henning, S.W., and Wagner, A.H. (2008). Chapter 7 Decoy Oligodeoxynucleotides to Treat Inflammatory Diseases. Therapeutic Oligonucleotides, The Royal Society of Chemistry.","DOI":"10.1039\/9781847558275-00163"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1093\/nar\/30.11.2435","article-title":"Design and characterization of decoy oligonucleotides containing locked nucleic acids","volume":"30","author":"Crinelli","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0014-5793(03)00689-6","article-title":"Specific covalent binding of a NF-kappaB decoy hairpin oligonucleotide targeted to the p50 subunit and induction of apoptosis","volume":"547","author":"Lesage","year":"2003","journal-title":"FEBS Lett."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1038\/sj.onc.1206733","article-title":"Use of adeno-associated viral vector for delivery of small interfering RNA","volume":"22","author":"Tomar","year":"2003","journal-title":"Oncogene"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1021\/bi982515x","article-title":"Selection and characterization of an RNA decoy for transcription factor NF-kappa B","volume":"38","author":"Lebruska","year":"1999","journal-title":"Biochemistry"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.omtm.2019.01.008","article-title":"Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors","volume":"12","author":"Srivastava","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/ng0303-331","article-title":"Fibrillin controls TGF-beta activation","volume":"33","author":"Kaartinen","year":"2003","journal-title":"Nat. Genet."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.jvs.2012.10.007","article-title":"The fibrillin-1 hypomorphic mgR\/mgR murine model of Marfan syndrome shows severe elastolysis in all segments of the aorta","volume":"57","author":"Schwill","year":"2013","journal-title":"J. Vasc. Surg."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1024\/0301-1526\/a000609","article-title":"Glutathione system participation in thoracic aneurysms from patients with Marfan syndrome","volume":"46","author":"Soto","year":"2017","journal-title":"Vasa"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/gt.2011.143","article-title":"Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors","volume":"19","author":"Varadi","year":"2012","journal-title":"Gene Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/CIRCRESAHA.111.253740","article-title":"miR-29b participates in early aneurysm development in Marfan syndrome","volume":"110","author":"Merk","year":"2012","journal-title":"Circ. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e13257","DOI":"10.14814\/phy2.13257","article-title":"Long-term miR-29b suppression reduces aneurysm formation in a Marfan mouse model","volume":"5","author":"Okamura","year":"2017","journal-title":"Physiol. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1161\/ATVBAHA.116.307841","article-title":"Resveratrol Inhibits Aortic Root Dilatation in the Fbn1C1039G\/+ Marfan Mouse Model","volume":"36","author":"Hibender","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"van Andel, M.M., Groenink, M., Zwinderman, A.H., Mulder, B.J.M., and de Waard, V. (2019). The Potential Beneficial Effects of Resveratrol on Cardiovascular Complications in Marfan Syndrome Patients(-)Insights from Rodent-Based Animal Studies. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20051122"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12967-018-1429-3","article-title":"Deregulated microRNA and mRNA expression profiles in the peripheral blood of patients with Marfan syndrome","volume":"16","author":"Kahraman","year":"2018","journal-title":"J. Transl. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/sj.gt.3303069","article-title":"Overexpression of PAI-1 prevents the development of abdominal aortic aneurysm in mice","volume":"15","author":"Qian","year":"2008","journal-title":"Gene Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/ejcts\/ezu415","article-title":"Histology of a Marfan aorta 4.5 years after personalized external aortic root support","volume":"48","author":"Pepper","year":"2015","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Verhagen, J.M.A., Burger, J., Bekkers, J.A., den Dekker, A.T., von der Thusen, J.H., Zajec, M., Bruggenwirth, H.T., van der Sterre, M.L.T., van den Born, M., and Luider, T.M. (2021). Multi-Omics Profiling in Marfan Syndrome: Further Insights into the Molecular Mechanisms Involved in Aortic Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23010438"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1161\/ATVBAHA.120.314670","article-title":"Single-Cell Transcriptomic Profiling of Vascular Smooth Muscle Cell Phenotype Modulation in Marfan Syndrome Aortic Aneurysm","volume":"40","author":"Pedroza","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Dawson, A., Li, Y., Li, Y., Ren, P., Vasquez, H.G., Zhang, C., Rebello, K.R., Ageedi, W., Azares, A.R., and Mattar, A.B. (2021). Single-Cell Analysis of Aneurysmal Aortic Tissue in Patients with Marfan Syndrome Reveals Dysfunctional TGF-beta Signaling. Genes, 13.","DOI":"10.3390\/genes13010095"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/ng.3723","article-title":"An iPSC-derived vascular model of Marfan syndrome identifies key mediators of smooth muscle cell death","volume":"49","author":"Granata","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1024\/0301-1526\/a000002","article-title":"Marfan syndrome and the evolving spectrum of heritable thoracic aortic disease: Do we need genetics for clinical decisions?","volume":"39","author":"Rybczynski","year":"2010","journal-title":"Vasa"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/s41436-021-01132-x","article-title":"Clinical relevance of genotype-phenotype correlations beyond vascular events in a cohort study of 1500 Marfan syndrome patients with FBN1 pathogenic variants","volume":"23","author":"Arnaud","year":"2021","journal-title":"Genet. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/cge.13879","article-title":"Genotype FBN1\/phenotype relationship in a cohort of patients with Marfan syndrome","volume":"99","author":"Valera","year":"2021","journal-title":"Clin. Genet."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jbi.2005.06.001","article-title":"A bioinformatics framework for genotype-phenotype correlation in humans with Marfan syndrome caused by FBN1 gene mutations","volume":"39","author":"Baumgartner","year":"2006","journal-title":"J. Biomed. Inform."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1053\/j.semperi.2018.09.003","article-title":"CRISPR\/Cas9 gene-editing: Research technologies, clinical applications and ethical considerations","volume":"42","author":"Memi","year":"2018","journal-title":"Semin. Perinatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.ymthe.2018.08.007","article-title":"Correction of the Marfan Syndrome Pathogenic FBN1 Mutation by Base Editing in Human Cells and Heterozygous Embryos","volume":"26","author":"Zeng","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature23305","article-title":"Correction of a pathogenic gene mutation in human embryos","volume":"548","author":"Ma","year":"2017","journal-title":"Nature"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/14\/3934\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:43:28Z","timestamp":1760139808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/14\/3934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,6]]},"references-count":67,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["jcm11143934"],"URL":"https:\/\/doi.org\/10.3390\/jcm11143934","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,6]]}}}